GUGGENHEIM CAPITAL LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
GUGGENHEIM CAPITAL LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$918,237
+1.8%
25,757
+31.7%
0.01%
+14.3%
Q2 2023$901,841
-3.1%
19,550
-15.7%
0.01%
-12.5%
Q1 2023$930,480
-34.7%
23,204
-24.5%
0.01%
-38.5%
Q4 2022$1,424,648
+13.5%
30,750
+1.5%
0.01%
+18.2%
Q3 2022$1,255,000
-30.8%
30,309
-0.3%
0.01%
-21.4%
Q2 2022$1,814,000
-13.8%
30,399
+4.9%
0.01%
+7.7%
Q1 2022$2,104,000
-9.1%
28,984
+5.3%
0.01%
+8.3%
Q4 2021$2,315,000
+4.0%
27,524
+11.5%
0.01%
-7.7%
Q3 2021$2,226,000
-5.8%
24,679
-0.4%
0.01%
-7.1%
Q2 2021$2,364,000
-6.7%
24,788
+11.4%
0.01%
-17.6%
Q1 2021$2,533,000
-0.4%
22,245
+21.0%
0.02%
+6.2%
Q4 2020$2,544,000
-2.9%
18,379
-42.3%
0.02%
-15.8%
Q3 2020$2,619,000
-19.3%
31,865
-23.2%
0.02%
-24.0%
Q2 2020$3,246,000
+50.3%
41,493
-14.6%
0.02%
+13.6%
Q1 2020$2,159,000
-13.0%
48,601
-16.4%
0.02%
+15.8%
Q4 2019$2,483,000
+22.3%
58,140
+22.5%
0.02%
+18.8%
Q3 2019$2,031,000
-26.7%
47,468
+8.8%
0.02%
-30.4%
Q2 2019$2,770,000
-13.0%
43,629
-5.0%
0.02%
-11.5%
Q1 2019$3,185,000
+48.3%
45,925
-7.0%
0.03%
+44.4%
Q4 2018$2,148,000
-38.5%
49,401
+8.0%
0.02%
-21.7%
Q3 2018$3,491,000
-4.0%
45,725
-3.4%
0.02%
-4.2%
Q2 2018$3,638,000
+23.8%
47,330
-17.9%
0.02%
+242.9%
Q1 2018$2,939,000
+10.9%
57,647
+1.0%
0.01%
+16.7%
Q4 2017$2,649,000
-27.9%
57,102
-17.2%
0.01%
-33.3%
Q3 2017$3,675,000
+12.9%
68,994
+31.7%
0.01%0.0%
Q2 2017$3,254,000
+5.0%
52,405
+14.6%
0.01%
+12.5%
Q1 2017$3,098,000
-6.7%
45,721
-3.2%
0.01%
-11.1%
Q4 2016$3,320,000
-10.3%
47,217
-9.5%
0.01%
-25.0%
Q3 2016$3,701,000
+28.7%
52,177
-11.2%
0.01%
+33.3%
Q2 2016$2,875,000
-61.0%
58,774
-10.6%
0.01%
-57.1%
Q4 2015$7,372,000
+31.8%
65,713
+13.1%
0.02%
+23.5%
Q3 2015$5,595,000
+108.9%
58,091
+122.1%
0.02%
+142.9%
Q2 2015$2,678,000
-29.4%
26,159
-61.0%
0.01%
-22.2%
Q3 2014$3,795,00067,0430.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders